AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. RDY
  4. [6-K] Dr. Reddy's Laboratories Limited American Current Report (Foreign Issuer)

[6-K] Dr. Reddy's Laboratories Limited American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock RDY logo
Dr Reddys Labs

NYSE:RDY

RDY Rankings

#1127 Ranked by Market Cap
#1938 Ranked by Dividends

RDY Latest News

Jul 23, 2025
Dr. Reddy’s Q1FY26 Financial Results
May 9, 2025
Dr. Reddy’s Q4 & Full Year FY25 Financial Results
Mar 27, 2025
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
Mar 18, 2025
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Mar 13, 2025
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

RDY Latest SEC Filings

Jul 25, 2025
[6-K] Dr. Reddy's Laboratories Limited American Current Report (Foreign Issuer)
Jul 25, 2025
[6-K] Dr. Reddy's Laboratories Limited American Current Report (Foreign Issuer)
Jul 24, 2025
[6-K] Dr. Reddy's Laboratories Limited American Current Report (Foreign Issuer)
Jul 24, 2025
[6-K] Dr. Reddy's Laboratories Limited American Current Report (Foreign Issuer)
Jul 24, 2025
[6-K] Dr. Reddy's Laboratories Limited American Current Report (Foreign Issuer)

RDY Stock Data

12.15B
832.13M
15.04%
2.19%
Drug Manufacturers - Specialty & Generic
Healthcare
India
Hyderabad